Investigating how ponatinib affects heart cells and causes heart problems in cancer treatment.
Mitochondrial Dysfunction Underlies the Integrated Stress Response Activation in Ponatinib-Induced Cardiotoxicity
This study is looking at how the cancer drug ponatinib affects heart cells in people with chronic myeloid leukemia, hoping to find ways to protect the heart from any harmful side effects while treating cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10890168 on NIH RePORTER |
What this research studies
This research focuses on understanding the effects of ponatinib, a medication used to treat chronic myeloid leukemia, on heart cells. It aims to explore the mechanisms behind cardiotoxicity, which is a harmful side effect that can occur with this treatment. By examining how heart cells respond to stress and the integrated stress response activation, the study seeks to identify potential new therapies to protect the heart during cancer treatment. Patients may benefit from insights that could lead to safer cancer therapies with fewer cardiac complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are adult patients with chronic myeloid leukemia who are being treated with ponatinib.
Not a fit: Patients who are not receiving ponatinib or those with pre-existing severe heart conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that minimize heart damage in cancer patients receiving ponatinib.
How similar studies have performed: Previous research has shown that understanding cellular responses to cancer therapies can lead to significant advancements in mitigating side effects, suggesting potential success for this approach.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Lee, Won Hee — University of Arizona
- Study coordinator: Lee, Won Hee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.